DB:BX2

Stock Analysis Report

Executive Summary

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States.


Snowflake Analysis

Adequate balance sheet and slightly overvalued.

Share Price & News

How has BioXcel Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BX2's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-14.6%

BX2

-4.1%

DE Biotechs

-5.7%

DE Market


1 Year Return

309.0%

BX2

3.7%

DE Biotechs

6.1%

DE Market

Return vs Industry: BX2 exceeded the German Biotechs industry which returned 3.7% over the past year.

Return vs Market: BX2 exceeded the German Market which returned 6.1% over the past year.


Shareholder returns

BX2IndustryMarket
7 Day-14.6%-4.1%-5.7%
30 Day94.7%-8.2%-5.7%
90 Day382.6%-2.0%-3.6%
1 Year309.0%309.0%4.0%3.7%9.3%6.1%
3 Yearn/a38.2%36.7%8.9%-0.7%
5 Yearn/a9.9%7.5%13.6%-2.0%

Price Volatility Vs. Market

How volatile is BioXcel Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is BioXcel Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BX2 (€29.2) is trading below our estimate of fair value (€152.96)

Significantly Below Fair Value: BX2 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BX2 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: BX2 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BX2's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BX2 is overvalued based on its PB Ratio (15.6x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is BioXcel Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

55.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BX2 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BX2 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BX2 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if BX2's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if BX2's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BX2 is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has BioXcel Therapeutics performed over the past 5 years?

-115.8%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: BX2 is currently unprofitable.

Growing Profit Margin: BX2 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if BX2's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare BX2's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BX2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: BX2 has a negative Return on Equity (-92.3%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is BioXcel Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: BX2's short term assets ($41.4M) exceed its short term liabilities ($8.2M).

Long Term Liabilities: BX2's short term assets ($41.4M) exceed its long term liabilities ($1.1M).


Debt to Equity History and Analysis

Debt Level: BX2's debt to equity ratio (1.2%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if BX2's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: BX2 has a low level of unsold assets or inventory.

Debt Coverage by Assets: BX2's debt is covered by short term assets (assets are 98.5x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BX2 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BX2 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -83.3% each year


Next Steps

Dividend

What is BioXcel Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate BX2's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BX2's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BX2's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BX2's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BX2's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Vimal Mehta (58yo)

2.8yrs

Tenure

US$701,609

Compensation

Dr. Vimal D. Mehta, Ph.D., is Co-founder of BioXcel Corporation and serves as its Chairman and Chief Executive Officer. He has been Chief Executive Officer, President and Secretary of BioXcel Therapeutics, ...


CEO Compensation Analysis

Compensation vs Market: Vimal's total compensation ($USD701.61K) is below average for companies of similar size in the German market ($USD1.20M).

Compensation vs Earnings: Vimal's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Vimal Mehta
Founder2.8yrsUS$701.61k0.055% $328.3k
Frank Yocca
Chief Scientific Officer2.7yrsUS$654.41k0.49% $2.9m
Vincent O'Neill
Senior VP & Chief Medical Officer2.6yrsUS$663.30k0.37% $2.2m
Richard Steinhart
Chief Financial Officer2.3yrsUS$447.29k0.0083% $49.5k
Chids Mahadevan
VP of Finance & Chief Accounting Officer0yrsno datano data
Cedric Burg
VP and Head of Global Clinical Operations & Project Management1.7yrsno datano data
David Hanley
Head of Global Pharmaceutical Development and Operations & VP1.4yrsno datano data
Chetan Lathia
Senior VP and Head of Translational Medicine1.4yrsno datano data
Robert Risinger
Vice President of Clinical Development1.1yrsno datano data

2.0yrs

Average Tenure

58yo

Average Age

Experienced Management: BX2's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Vimal Mehta
Founder2.8yrsUS$701.61k0.055% $328.3k
Krishnan Nandabalan
Director2.8yrsno data0.0055% $32.9k
Steven Paul
Member of Advisory Board0yrsno datano data
Peter Mueller
Chairman of the Board of Directors2.5yrsUS$336.71k0.93% $5.5m
Alan Breier
Member of Clinical Advisory Board1.6yrsno datano data
Stephen Marder
Member of Clinical Advisory Board1.6yrsno datano data
Sheldon Preskorn
Member of Clinical Advisory Board1.6yrsno datano data
Sandeep Laumas
Independent Director2.4yrsUS$315.04k0.29% $1.7m
Sheila Gujrathi
Member of Advisory Board0yrsno datano data
George Grossberg
Member of Clinical Advisory Board1.6yrsno datano data

2.0yrs

Average Tenure

57yo

Average Age

Experienced Board: BX2's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.3%.


Top Shareholders

Company Information

BioXcel Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioXcel Therapeutics, Inc.
  • Ticker: BX2
  • Exchange: DB
  • Founded: 2017
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$646.814m
  • Listing Market Cap: US$594.551m
  • Shares outstanding: 20.09m
  • Website: https://www.bioxceltherapeutics.com

Number of Employees


Location

  • BioXcel Therapeutics, Inc.
  • 555 Long Wharf Drive
  • 5th Floor
  • New Haven
  • Connecticut
  • 6511
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BTAINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMar 2018
BX2DB (Deutsche Boerse AG)YesCommon StockDEEURMar 2018

Biography

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA, Nektar Therapeutics, and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 23:41
End of Day Share Price2020/02/25 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.